Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

February 2023 in “ Advances in Therapy ”

Peter C Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Walter Deberdt, Maher Issa, Ewa Haladyj, Inmaculada de la Torre, Susanne Grond, Andreas Wollenberg

Baricitinib alopecia areata atopic dermatitis rheumatoid arthritis major adverse cardiovascular events malignancies venous thromboembolism serious infection mortality hair regrowth AA AD RA

From the encyclopedia

Baricitinib →

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials

25 citations , November 2022 in “British journal of dermatology/British journal of dermatology, Supplement”

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research Comorbidities in Alopecia Areata: A Systematic Review and Meta-Analysis

100 citations , July 2018 in “Journal of The American Academy of Dermatology”

This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.

research Cancer Risk by the Subtype of Alopecia

9 citations , June 2018 in “Scientific Reports”

This study reported that patients with alopecia areata or alopecia totalis/universalis have a slightly increased overall cancer risk compared to controls, with specific increases in thyroid, bladder, and prostate cancers depending on the alopecia type.

research Cancer Risk in Patients with Alopecia Areata: A Nationwide Population-Based Matched Cohort Study

15 citations , March 2018 in “Cancer Medicine”

This study found that alopecia areata patients had a slightly decreased overall cancer risk, with significantly lower risks for some cancers but higher risks for lymphoma, breast, kidney, and urinary bladder cancers.

research Cardiovascular Risk in Patients with Alopecia Areata: A Propensity-Matched Retrospective Analysis

29 citations , May 2016 in “Journal of the American Academy of Dermatology”

This study observed that patients with alopecia areata had decreased odds of developing stroke and a potential decreased risk of acute myocardial infarction, though the latter was not statistically significant.